The Board announces that on 15th February 2007, Xiamen TCM, a subsidiary of the Company, has entered into a
distribution agreement with Xiamen Medicine Centre for a term of one year. Pursuant to which, Xiamen TCM
shall sell pharmaceutical products to Xiamen Medicine Centre.

Xiamen Medicine Centre is a wholly-owned subsidiary of Xiamen Qing Gong Group Co. Ltd.* (廈門輕工集團
有限公司) which is a substantial shareholder of Xiamen TCM. Accordingly, Xiamen Medicine Centre is a
connected person of the Company under the Listing Rules.

Pursuant to the Listing Rules, the Sales Transactions constitute continuing connected transactions of the Company.
As the relevant percentage ratios represented by the expected maximum aggregate annual sales for the year 2007 of
RMB15 million exceed 0.1% but are less than 2.5%, the Sales Transactions are exempt from the independent
shareholders’ approval requirements but are subject to the reporting and announcement requirements set out in
Rules 14A.45 to 14A.47 of the Listing Rules.

SALES TRANSACTIONS
The Board of Directors (the “Board”) of Shanghai Industrial Holdings Limited (the “Company”) announces that on 15th
February 2007, Xiamen Traditional Chinese Medicine Co. Ltd. (“Xiamen TCM”), a
subsidiary of the Company, has entered into a distribution agreement with Fujian Province Xiamen Medicine
Procurement Centre* (福建省廈門醫藥採購供應站) (“Xiamen Medicine Centre”) for a term of one year (the
“Agreement”). Pursuant to which, Xiamen TCM shall sell pharmaceutical products to Xiamen Medicine Centre (the
“Sales Transactions”).

CONSIDERATION
The selling prices will be determined by the parties on arm’s length negotiations based on market prices and having
regard to the quantity and/or other conditions of the products to be offered. The aggregate annual sales by Xiamen TCM
to Xiamen Medicine Centre for the years 2004, 2005 and 2006 amounted to RMB8.8 million, RMB7.8 million and
RMB6.9 million respectively. With reference to the amount of historical transactions and the preliminary projected
annual supply schedule, Xiamen TCM expects that the maximum aggregate annual sales for the year 2007 (the “Annual
Cap”) is RMB15 million.

CONTINUING CONNECTED TRANSACTIONS
Xiamen TCM is a subsidiary of the Company. Xiamen Medicine Centre is a wholly-owned subsidiary of Xiamen Qing
Gong Group Co. Ltd.* (廈門輕工集團有限公司) which is a substantial shareholder of Xiamen TCM. Accordingly, Xiamen Medicine Centre is a
connected person of the Company under the Rules Governing the Listing of Securities of
The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

Pursuant to the Listing Rules, the Sales Transactions constitute continuing connected transactions of the Company. As
the relevant percentage ratios represented by the Annual Cap of RMB15 million exceed 0.1% but are less than 2.5%, the
Sales Transactions are exempt from the independent shareholders’ approval requirements but are subject to the reporting
and announcement requirements set out in Rules 14A.45 to 14A.47 of the Listing Rules.

REASONS FOR THE CONTINUING CONNECTED TRANSACTIONS
Xiamen TCM and the traditional chinese medicine business unit of Xiamen Medicine Centre had on 29th March 2004
entered into a sales agreement in relation to the Sales Transactions. The said agreement expired on 31st December 2006.
Both parties intend to renew the agreement on an annual basis.

The sale of pharmaceutical products by Xiamen TCM to Xiamen Medicine Centre will help to strengthen and increase
the market share of pharmaceutical products of Xiamen TCM and increase Xiamen TCM’s sales revenue.
The Agreement is entered into in the ordinary and usual course of business of Xiamen TCM and on normal commercial terms. The Board (including the Independent Non-Executive Directors) considers that the terms of the Agreement are fair and reasonable and in the best interest of the shareholders of the Company as a whole.

GENERAL INFORMATION

The Company and its subsidiaries are principally engaged in the business of infrastructure facilities, medicine, consumer products and information technology. Xiamen TCM, a 61% owned indirect subsidiary of the Company, is principally engaged in the business of manufacturing and sale of Chinese medicine. Xiamen Medicine Centre is principally engaged in the business of retail and distribution of pharmaceutical products.

For the purposes of this announcement, the exchange rate at HK$1 = RMB1 has been used, where applicable, for purpose of illustration only and does not constitute a representation that any amounts were or may have been exchanged at these or any other rates or at all.

By Order of the Board
Shanghai Industrial Holdings Limited
Wong Mei Ling, Marina
Company Secretary

Hong Kong, 15th February 2007

As at the date of this announcement, the board of directors of the Company comprises eight Executive Directors, namely, Mr. Cai Lai Xing, Mr. Cai Yu Tian, Mr. Qu Ding, Mr. Lu Ming Fang, Mr. Ding Zhong De, Mr. Qian Shi Zheng, Mr. Yao Fang and Mr. Tang Jun; and three Independent Non-Executive Directors, namely, Dr. Lo Ka Shui, Prof. Woo Chia-Wei and Mr. Leung Pak To, Francis.

* The English name is an informal English translation of the official Chinese name.

Please also refer to the published version of this announcement in South China Morning Post.